Results 111 to 120 of about 3,528 (147)

Perinatal outcomes and sinopharm BBIBP-CorV vaccination during pregnancy. [PDF]

BMC Pregnancy Childbirth
Hatami D, Habibelahi A, Changizi N, Heidarzadeh M, Nojomi M, Rast M, Ansari K, Tehrani-Banihashemi A.   +7 more
europepmc   +1 more source

Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka. [PDF]

PLOS Glob Public Health, 2022
Jeewandara C, Jayampathi KACS, Ranasinghe T, Aberathna IS, Gunasekara B, Danasekara S, Nimasha T, Kuruppu H, Dissanayake O, Gamalath N, Ekanayake D, Jayamali J, Somathilake G, Guruge D, Wijayamuni R, Kamaladasa A, Ogg GS, Malavige GN.   +17 more
europepmc   +1 more source

Correction: Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco. [PDF]

PLoS One
Belayachi J, Obtel M, Mhayi A, Razine R, Abouqal R.   +4 more
europepmc   +1 more source

Investigating the impact of prior COVID-19 on IgG antibody and interferon γ responses after BBIBP-CorV vaccination in a disease endemic population: A prospective observational study. [PDF]

Health Sci Rep, 2023
Hasan Z, Masood KI, Qaiser S, Khan E, Hussain A, Ghous Z, Khan U, Yameen M, Hassan I, Nasir MI, Qazi MF, Memon HA, Ali S, Baloch S, Bhutta ZA, Veldhoen M, Pedro Simas J, Mahmood SF, Ghias K, Hussain R.   +19 more
europepmc   +1 more source

Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data. [PDF]

JMIR Res Protoc
Burhan E, Azzumar F, Sinuraya FAG, Rakasiwi MID, Akbar I, Mubarak F, Rengganis AT, Rachmadi RA, Afidjati H.   +8 more
europepmc   +1 more source

Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination. [PDF]

Res Pract Thromb Haemost, 2022
Hosseinzadeh R, Barary M, Mehdinezhad H, Sio TT, Langer F, Khosravi S.   +5 more
europepmc   +1 more source

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10-17 Years in Thailand. [PDF]

Vaccines (Basel), 2022
Thonginnetra S, Tawinprai K, Niemsorn K, Promsena P, Tandhansakul M, Kasemlawan N, Ruangkijpaisal N, Banomyong N, Phattraprayoon N, Rangkakulnuwat P, Vanichsetakul P, Ungtrakul T, Wittayasak K, Thonwirak N, Soonklang K, Mahanonda N.   +15 more
europepmc   +1 more source

Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study. [PDF]

BMC Neurol
Jameie M, Azizmohammad Looha M, Ebadi Z, Amanollahi M, Amani K, Nobahari F, Abdollahi A, Mousavi M, Pourghaz B, Harirchian MH.   +9 more
europepmc   +1 more source

FAKHRAVAC and BBIBP-CorV vaccine seeds’ binding to angiotensin-converting enzyme 2: A comparative molecular dynamics study

, 2023
Setareh S, Rad I, Meghdadi J, Khodayari K, Karimi Rahjerdi A.   +4 more
europepmc   +1 more source

Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population. [PDF]

PLoS One
Theresa Pool SN, Shroff EH, Chetty A, Lewis L, Nonhlanhla YZ, Abdool Karim SS.   +5 more
europepmc   +1 more source